MedGenome Inc. Sustainability Profile
MedGenome Inc., headquartered in the United States, is a leading player in the genomics and biotechnology industry, specialising in genomic testing and research services. Founded in 2013, the company has established a strong presence in major operational regions, including India and other parts of Asia, focusing on advancing precision medicine through innovative genetic solutions. MedGenome's core offerings include comprehensive genomic testing, bioinformatics services, and research collaborations, which are distinguished by their commitment to high-quality data and actionable insights. The company has achieved significant milestones, including partnerships with renowned institutions and contributions to large-scale genomic studies, positioning itself as a trusted leader in the field. With a focus on empowering healthcare through genomics, MedGenome continues to drive advancements in personalised medicine and genetic research.
DitchCarbon Score
How does MedGenome Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MedGenome Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MedGenome Inc.'s reported carbon emissions
MedGenome Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that MedGenome may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments, it is unclear how MedGenome aligns with these industry trends. As the company continues to operate, it may consider developing and communicating its climate strategies to enhance transparency and accountability in its environmental impact.
How Carbon Intensive is MedGenome Inc.'s Industry?
How Carbon Intensive is MedGenome Inc.'s Location?
MedGenome Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
MedGenome Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
